Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,837 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI, Inoue T, Higashi Y, Ueda S, Node K; EMBLEM Trial Investigators. Tanaka A, et al. Among authors: yoshida h. Cardiovasc Diabetol. 2017 Apr 12;16(1):48. doi: 10.1186/s12933-017-0532-8. Cardiovasc Diabetol. 2017. PMID: 28403850 Free PMC article. Clinical Trial.
Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K; PROLOGUE Study Investigators. Yamada H, et al. Among authors: yoshida h. Cardiovasc Diabetol. 2017 May 11;16(1):63. doi: 10.1186/s12933-017-0546-2. Cardiovasc Diabetol. 2017. PMID: 28490337 Free PMC article. Clinical Trial.
Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study.
Tanaka A, Yoshida H, Nanasato M, Oyama JI, Ishizu T, Ajioka M, Ishiki R, Saito M, Shibata Y, Kaku K, Maemura K, Higashi Y, Inoue T, Murohara T, Node K. Tanaka A, et al. Among authors: yoshida h. Int J Cardiol. 2018 Nov 15;271:331-335. doi: 10.1016/j.ijcard.2018.05.055. Epub 2018 May 19. Int J Cardiol. 2018. PMID: 29803341 Clinical Trial.
Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial.
Tanaka A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima KR, Takamura T, Taguchi I, Hisauchi I, Toyoda S, Matsuzawa Y, Tomiyama H, Yamaoka-Tojo M, Yoshida H, Sato Y, Ikehara Y, Ueda S, Higashi Y, Node K; EMBLEM Investigators. Tanaka A, et al. Among authors: yoshida h. Diabetes Care. 2019 Oct;42(10):e159-e161. doi: 10.2337/dc19-1177. Epub 2019 Sep 18. Diabetes Care. 2019. PMID: 31533913 No abstract available.
Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design.
Fujiki S, Iijima K, Okabe M, Niwano S, Tsujita K, Naito S, Ando K, Kusano K, Kato R, Nitta J, Miura T, Mitsuhashi T, Kario K, Kondo Y, Ieda M, Hagiwara N, Murohara T, Takahashi K, Tomita H, Takeishi Y, Anzai T, Shimizu W, Watanabe M, Morino Y, Kato T, Tada H, Nakagawa Y, Yano M, Maemura K, Kimura T, Yoshida H, Ota K, Tanaka T, Kitamura N, Node K, Aizawa Y, Shimizu I, Izumi D, Ozaki K, Minamino T; EMPA-ICD investigators. Fujiki S, et al. Among authors: yoshida h. Diabetes Ther. 2020 Nov;11(11):2739-2755. doi: 10.1007/s13300-020-00924-9. Epub 2020 Sep 23. Diabetes Ther. 2020. PMID: 32968947 Free PMC article.
7,837 results